Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity.
OBJECTIVE
Antidepressants that increase serotonin or norepinephrine in the brain are effective in treating depression, but there is no neuropsychological account of how these changes relieve depressive states. Cognitive theories suggest that biases in information processing lead depressed patients to make unrealistically negative judgments about themselves and the world.


METHODS
A single dose of the noradrenergic antidepressant reboxetine or placebo was administered to 24 healthy volunteers. Effects on emotional processing were assessed through facial expression recognition, emotional categorization, and emotional memory.


RESULTS
On the three measures, reboxetine biased perception toward positive, rather than negative, information in the absence of changes in nonemotional performance or mood.


CONCLUSIONS
These results suggest that a single dose of an antidepressant can increase the processing of positively valenced material in nondepressed volunteers. Antidepressants may therefore work in a manner similar to that of psychological treatments that aim to redress negative biases in information processing.
Department of Psychiatry, Oxford University, Warneford Hospital, Oxford OX3 7JX, USA. catherine.harmer@psych.ox.ac.uk
Catherine J
CJ
Harmer
Simon A
SA
Hill
Matthew J
MJ
Taylor
Philip J
PJ
Cowen
Guy M
GM
Goodwin
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000339:Affect / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004192:Discrimination, Psychological / Q000187:drug effects; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects*; D005149:Facial Expression; D005260:Female; D006240:Happiness; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D008954:Models, Biological; D008960:Models, Psychological; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D009341:Negativism; D009480:Neuropharmacology; D009483:Neuropsychological Tests; D010551:Personality / Q000145:classification; D000077593:Reboxetine
D018759:Adrenergic Uptake Inhibitors; D009025:Morpholines; D000077593:Reboxetine